Scientific article

Pacritinib: a new agent for the management of myelofibrosis?

Published inExpert opinion on pharmacotherapy, vol. 16, no. 15, p. 2381-2390
Publication date2015

Myelofibrosis (MF) is a clonal haematological disease associated with recurrent somatic gene mutations (JAK2V617F, MPL, CALR) and constitutive activation of the Janus kinase (JAK)/Signal Transducer and Activator of Transcription pathway. MF is often characterised by debilitating symptoms and JAK inhibitors (JAKIs) have revolutionised available therapeutic options. Ruxolitinib, a JAK1 and 2 inhibitor, is the only currently approved agent. Several other JAKIs are undergoing evaluation in the clinical trial setting and Pacritinib , a novel JAK2 and FLT3 inhibitor, is at an advanced stage of investigation with recent completion of a Phase III trial and another ongoing.

Affiliation Not a UNIGE publication
Citation (ISO format)
BEAUVERD, Yan, MCLORNAN, Donal P, HARRISON, Claire N. Pacritinib: a new agent for the management of myelofibrosis? In: Expert opinion on pharmacotherapy, 2015, vol. 16, n° 15, p. 2381–2390. doi: 10.1517/14656566.2015.1088831
Main files (1)
Article (Published version)
ISSN of the journal1465-6566

Technical informations

Creation01/27/2016 11:48:00 AM
First validation01/27/2016 11:48:00 AM
Update time03/15/2023 12:23:52 AM
Status update03/15/2023 12:23:52 AM
Last indexation01/16/2024 8:54:36 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack